1. Home
  2. RVSN vs QNRX Comparison

RVSN vs QNRX Comparison

Compare RVSN & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rail Vision Ltd.

RVSN

Rail Vision Ltd.

HOLD

Current Price

$4.88

Market Cap

10.9M

Sector

N/A

ML Signal

HOLD

Logo Quoin Pharmaceuticals Ltd.

QNRX

Quoin Pharmaceuticals Ltd.

SELL

Current Price

$4.90

Market Cap

11.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RVSN
QNRX
Founded
2016
2018
Country
Israel
United States
Employees
47
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9M
11.6M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
RVSN
QNRX
Price
$4.88
$4.90
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.2K
23.1K
Earning Date
03-31-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$860.32
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$4.80
52 Week High
$9.39
$41.80

Technical Indicators

Market Signals
Indicator
RVSN
QNRX
Relative Strength Index (RSI) 21.48 29.59
Support Level $0.31 N/A
Resistance Level $9.07 $6.84
Average True Range (ATR) 0.38 0.43
MACD -0.20 -0.10
Stochastic Oscillator 6.35 8.57

Price Performance

Historical Comparison
RVSN
QNRX

About RVSN Rail Vision Ltd.

Rail Vision Ltd is an early commercialization stage technology company focused on railway safety systems using AI-integrated sensing systems. The company develops and commercializes proprietary, multi-spectral electro-optic platforms that provide extended-range situational awareness and real-time hazard detection. Using machine learning algorithms to identify and classify obstacles, the company's technology enhances safety, improves operational efficiency, and supports continuity across deployments.

About QNRX Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Share on Social Networks: